Chloe Orkin
Overview
Explore the profile of Chloe Orkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
4177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apea V, Whelan I, Kinsella S, Orkin C
BMJ Open
. 2025 Mar;
15(3):e086922.
PMID: 40074269
Objectives: Racially minoritised communities (RMCs) were disproportionately affected by COVID-19, experiencing among the highest mortality rates of the UK's pandemic. We sought to understand the priorities for action to address...
2.
Mussini C, Girardi E, Milic J, Guaraldi G, Orkin C
Clin Microbiol Infect
. 2025 Mar;
PMID: 40043908
No abstract available.
3.
Apea V, Titanji B, Dakin F, Hayes R, Smuk M, Kawu H, et al.
PLOS Glob Public Health
. 2025 Feb;
5(2):e0003704.
PMID: 39951482
In May 2022, the most widespread outbreak of sustained transmission of mpox outside of countries historically affected countries in Western and Central Africa occurred. We aimed to examine the personal...
4.
Iwuji C, Waters L, Milinkovic A, Orkin C, Fox J, Post F, et al.
Virol J
. 2025 Feb;
22(1):33.
PMID: 39930490
Background: There are limited data on how historical nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs) other than M184V/I, affect the activity of B/F/TAF. We evaluated the outcomes of switching...
5.
Ring K, Orkin C
Curr Opin HIV AIDS
. 2024 Dec;
20(1):4-10.
PMID: 39633535
Purpose Of Review: Long-acting antiretroviral therapy (ART), such as with cabotegravir and rilpivirine, is a new and exciting paradigm shift that could change the face of HIV treatment if it...
6.
Orkin C, Hayes R, Haviland J, Wong Y, Ring K, Apea V, et al.
Clin Infect Dis
. 2024 Oct;
PMID: 39465685
Introduction: The equity-focused ILANA study evaluated feasibility, acceptability, appropriateness of delivering on-label two-monthly cabotegravir and rilpivirine (CAB+RPV) injections for HIV-1 therapy in clinics and community settings. Methods: The study, which...
7.
Palumbo L, Picchio C, Barbier F, Calderon-Cifuentes A, James J, Lunchenkov N, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae523.
PMID: 39355261
Between May 2022 and September 2023, the World Health Organization (WHO) Regional Office for Europe engaged in a collaborative effort with affected communities to address the outbreak of mpox in...
8.
Paparini S, Whelan I, Mwendera C, Hayes R, Maatouk I, Lewis R, et al.
Infect Dis (Lond)
. 2024 Jul;
56(8):589-605.
PMID: 38958049
Background: The ongoing multi-country mpox outbreak in previously unaffected countries is primarily affecting sexual networks of men who have sex with men. Evidence is needed on the effectiveness of recommended...
9.
Ring K, Smuk M, Shongwe M, Okonta L, Mackie N, Ayres S, et al.
HIV Med
. 2024 Jun;
25(10):1125-1134.
PMID: 38858222
Introduction: Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We...
10.
Saloniki E, Halvorsrud K, Whelan I, Halim N, George R, Orkin C
Med Humanit
. 2024 Jun;
50(3):555-560.
PMID: 38834295
Objectives: To explore how higher education institutions (HEIs) make transparent the data they collect on staff disability, and how this relates to existing equality, diversity and inclusion (EDI) charters. Design:...